Can Mirtazapine (Remeron) Be Used for Sleep in Bipolar Disorder While on Depakote 500mg?
Yes, mirtazapine can be safely prescribed at low doses (7.5-15 mg) for insomnia in this patient with bipolar disorder who is already on valproic acid (Depakote) 500 mg as a mood stabilizer.
Key Clinical Considerations
Safety Profile in Bipolar Disorder
The critical distinction is dose-dependent risk. Low-dose mirtazapine (7.5-15 mg) used specifically for sleep carries minimal risk of inducing mania when combined with mood stabilizer therapy 1. The FDA label warns about "mania or hypomania (manic episodes) in people who have a history of bipolar disorder" 2, but research demonstrates this risk is primarily associated with:
- Antidepressant doses (30-45 mg) without mood stabilizer coverage
- Monotherapy in bipolar patients
- Patients with additional risk factors for switching
Evidence Supporting Safe Use
A 2015 systematic review specifically examining sleep-promoting antidepressants found that low doses of mirtazapine used for hypnotic/sedative effects only caused mania in patients with other risk factors for switching 1. Importantly, there is no evidence that mirtazapine increases switching risk when combined with a mood stabilizer 1.
Practical Prescribing Approach
Start with 7.5-15 mg at bedtime:
- This dose targets the H1 (histamine) receptor antagonism for sedation
- Paradoxically, lower doses are MORE sedating than higher doses
- The FDA label notes sedation/sleepiness as a primary effect 2
Monitor for warning signs of mood destabilization:
- Greatly increased energy or racing thoughts
- Decreased need for sleep (distinct from improved sleep quality)
- Unusually grand ideas or reckless behavior
- Excessive happiness or irritability
Drug Interaction Profile
The combination is pharmacologically safe. The FDA label for Depakote does not list mirtazapine as a significant interaction 3, and the Remeron label shows minimal interactions with mood stabilizers 2. Specifically, lithium (another mood stabilizer) showed no relevant clinical effects when combined with mirtazapine 2.
Alternative Considerations
While the 2017 American Academy of Sleep Medicine guideline does not recommend trazodone for insomnia 4, it notably does not address mirtazapine at all, as mirtazapine is not FDA-approved specifically for insomnia. The guideline recommends FDA-approved agents like suvorexant, eszopiclone, or low-dose doxepin 4. However, in bipolar disorder, these alternatives lack the safety data that mirtazapine has accumulated.
Common Pitfalls to Avoid
- Do not use antidepressant doses (30-45 mg) without clear indication and close monitoring
- Do not discontinue the mood stabilizer - the Depakote 500 mg must be continued
- Avoid combining with benzodiazepines - the FDA label specifically warns about additive sedation 2
- Avoid alcohol - produces additive cognitive and motor impairment 2
Expected Adverse Effects at Low Doses
The most common side effects at sleep doses include 2, 5:
- Increased appetite and weight gain (most common)
- Morning drowsiness (dose-dependent)
- Dry mouth
- Dizziness
The patient should be counseled that weight gain is the primary concern, occurring in >10% of patients even at low doses.
Monitoring Parameters
- Mood stability (weekly for first month)
- Weight (monthly)
- Sleep quality improvement (should see benefit within 3-7 days)
- White blood cell count if fever or infections develop (rare agranulocytosis risk) 2
This recommendation prioritizes both the quality of life improvement from treating insomnia and the safety profile in bipolar disorder, given the patient is appropriately covered with a mood stabilizer.